New AI imaging technique enhances retinal disorder diagnosis

Population-based studies have shown retinal disorders are the most common cause of irreversible blindness in developed countries and the second most common cause of blindness after cataracts in developing countries.

FDA approves Mirum’s LIVMARLI for cholestatic pruritus treatment

Share this article Mirum Pharmaceuticals’s LIVMARLI (maralixibat) oral solution is now available in the US for cholestatic pruritus in patients with PFIC. Credit: Mirum Pharmaceuticals

March 14, 2024

AWS Launches $100M Generative AI Center to Accelerate Healthcare, Life Sciences

What You Should Know: Amazon Web Services, Inc. (AWS) announced an investment of $100M to launch the AWS Generative AI Innovation Center, with healthcare and

June 23, 2023

Study offers insights into chronic fatigue syndrome and its resemblance to long COVID-19

The study, which will serve “as a guide for rapid diagnosis”, provides valuable information for the medical community, in particular in primary care.

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.